Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration

被引:107
|
作者
Roger, Emilie [3 ]
Lagarce, Frederic [1 ,2 ]
Benoit, Jean-Pierre [2 ]
机构
[1] INSERM, Lab Ingn Vectorisat Particulaire, IFR132, Bat IRIS,U646, F-49033 Angers, France
[2] CHU Angers, Angers, France
[3] Ethypharm, F-92213 St Cloud, France
关键词
Lipid nanocapsule; Sn38; Caco-2; Stability; Oral administration; Nanotechnology; SN-38-INCORPORATING POLYMERIC MICELLES; REVERSES MULTIDRUG-RESISTANCE; ACTIVE METABOLITE SN-38; DRUG-DELIVERY SYSTEM; DNA TOPOISOMERASE-I; LIQUID-CHROMATOGRAPHY; IRINOTECAN CPT-11; INTESTINAL-CELLS; CAMPTOTHECIN; NANOCARRIERS;
D O I
10.1016/j.ejpb.2011.01.021
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this work was to encapsulate 7-Ethyl-10-hydroxy-camptothecin (Sn38) in lipid nanocapsules (LNCs) using phase inversion-based method in order to deliver Sn38 by oral route. LNCs were prepared by a low-energy emulsification method and were characterized for size, polydispersity index (PD!), surface charge, drug payload, in vitro drug release, and storage stability. Moreover, in view of an oral administration, in vitro stability in gastrointestinal fluid and permeability across Caco-2 cells were tested. Sn38-loaded LNCs with a mean particle size of 38 +/- 2 nm were obtained. The particles displayed a narrow size distribution and a drug payload of 0.40 +/- 0.07 mg/g of LNC dispersion. In vitro stability in simulated gastric and intestinal media was also observed. Finally, Sn38-loaded LNCs improved permeability of Sn38 across Caco-2 cells (5.69 +/- 0.87 x 10(6) cm s(-1) at 6 h vs 0.31 +/- 0.02 x 10(6) cm s(-1)) and intracellular concentration compared with free Sn38. In conclusion, Sn38 nanocarriers have been developed and display a strong potential for oral administration. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 50 条
  • [41] Lipid-assisted PEG-b-PLA nanoparticles with ultrahigh SN38 loading capability for efficient cancer therapy
    Huang, Xiaoyi
    Li, Jieyi
    Yang, Yanfang
    Wang, Zi-Lu
    Yang, Xian-Zhu
    Lu, Zi-Dong
    Xu, Cong-Fei
    BIOMATERIALS SCIENCE, 2023, 11 (22) : 7445 - 7457
  • [42] Novel Lipid Formulation Increases Absorption of Oral Cannabidiol (CBD)
    Chesney, Edward
    Mazibuko, Ndabezinhle
    Oliver, Dominic
    Minichino, Amedeo
    Lamper, Ayse Doga
    Chester, Lucy
    Reilly, Thomas J.
    Lloyd, Millie
    Krakstrom, Matilda
    Dickens, Alex M.
    Oresic, Matej
    Lynch, Eric
    Stoloff, Gregory
    Mehta, Mitul A.
    Mcguire, Philip
    PHARMACEUTICS, 2024, 16 (12)
  • [43] In vitro cytotoxicity, pharmacokinetics and tissue distribution in rats of MXN-004, a novel conjugate of polyethylene glycol and SN38
    Zhou, Sufeng
    Li, Ning
    Wang, Xin
    Li, Cuiyun
    Tian, Fengjie
    Ren, Shuangxia
    Zhang, Yuehua
    He, Yuanping
    Qiu, Zhixia
    Zhao, Di
    Chen, Xijing
    XENOBIOTICA, 2014, 44 (06) : 562 - 569
  • [44] Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors
    Fang, Tao
    Dong, Yuehan
    Zhang, Xiaomin
    Xie, Ke
    Lin, Li
    Wang, Hangxiang
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 512 (01) : 39 - 48
  • [45] The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: A comparative study with SN38 and topotecan
    Di Francesco, AM
    Riccardi, AS
    Barone, G
    Rutella, S
    Meco, D
    Frapolli, R
    Zucchetti, M
    D'Incalci, M
    Pisano, C
    Carminati, P
    Riccardi, R
    BIOCHEMICAL PHARMACOLOGY, 2005, 70 (08) : 1125 - 1136
  • [46] EZN-2208, A NOVEL PEGYLATED SN38 DRUG CONJUGATE, MARKEDLY INHIBITS TUMOR GROWTH IN COMPARISON TO IRINOTECAN
    Keir, Stephen T.
    Friedman, Henry S.
    Bigner, Darell D.
    NEURO-ONCOLOGY, 2012, 14 : 29 - 29
  • [47] Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11 - Refractory model
    Sapra, Puja
    Zhao, Hong
    Mehlig, Mary
    Malaby, Jennifer
    Kraft, Patricia
    Longley, Clifford
    Greenberger, Lee M.
    Horak, Ivan D.
    CLINICAL CANCER RESEARCH, 2008, 14 (06) : 1888 - 1896
  • [48] Safety, Pharmacokinetics, and Activity of EZN-2208, a Novel Conjugate of Polyethylene Glycol and SN38, in Patients With Advanced Malignancies
    Kurzrock, Razelle
    Goel, Sanjay
    Wheler, Jennifer
    Hong, David
    Fu, Siqing
    Rezai, Keyvan
    Morgan-Linnell, Sonia K.
    Urien, Saik
    Mani, Sridhar
    Chaudhary, Imran
    Ghalib, Mohammed H.
    Buchbinder, Aby
    Lokiec, Francois
    Mulcahy, Mary
    CANCER, 2012, 118 (24) : 6144 - 6151
  • [49] Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase I Inhibitor
    Pastorino, Fabio
    Loi, Monica
    Sapra, Puja
    Becherini, Pamela
    Cilli, Michele
    Emionite, Laura
    Ribatti, Domenico
    Greenberger, Lee M.
    Horak, Ivan D.
    Ponzoni, Mirco
    CLINICAL CANCER RESEARCH, 2010, 16 (19) : 4809 - 4821
  • [50] Novel solid lipid nanoparticles as carriers for oral administration of insulin
    Zhang, Zhenhai
    Lv, Huixia
    Zhou, Jianping
    PHARMAZIE, 2009, 64 (09): : 574 - 578